fda tirzepatide shortage resolved date says of GLP-1 drug is over Tirzepatide is NO longer in

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, distinguishing it from approved agents such as semaglutide or tirzepatide

A cross-sectional study revealed a potential association between DPP4 inhibitor use and an elevated risk of Hashimotos thyroiditis, psoriasis, and Crohns disease

Others prefer not to use medications long-term (12% of US adults have used GLP-1 medications in the past, Mozafariun et al, 2025)

6 Science-Backed Benefits of Yerba Mate Tea Mate, as the tea is commonly called outside the US, is the national drink of Paraguay, says Allison Birks, CDN, an herbalist and nutritionist

You may not even know exactly what youre getting or whether the dose is accurate from one administration to the next. Indeed, GLP-1 use without medical oversight heightens the risk of medication side effects, such as gallbladder disease, pancreatitis, thyroid conditions, retinopathy and nutrient deficiencies